ArticleBMC cancer2025

Prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation: a retrospective study.

Zhao-Dan Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.